- Facing pharmacy trends for the remainder of the year
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Senate passes Drug Quality and Security Act
- Cardinal Health’s Independence Medical unit helps pharmacy owners tap into growing home healthcare market
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
ALLEGAN, Mich. — Generic drug maker Perrigo reported sales of $2.76 billion and profits of $341 million in fiscal year 2011, according to an earnings report released Tuesday.
The company's sales represent a 21% increase over fiscal year 2010, while its profits represent a 52% increase. Much of the increase in sales came from the acquisition of PBM Holdings and Orion Labs, as well as $192 million in new product sales.
For fourth quarter 2011, which ended June 25, sales were $705 million, a 14% increase over fourth quarter 2010, while profits were $86 million, compared with $49 million a year ago.
Prescription drugs had sales of $92 million, a 12% increase over fourth quarter 2010's $83 million. OTC drugs had sales of $434 million, compared with $399 million last year; nutritionals had sales of $123 million, compared with $84 million last year; and active pharmaceutical ingredient sales decreased from $39 million to $37 million during the same period.